Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory pulmonary disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulties, coughing, mucus production, and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions.

The Chronic Obstructive Pulmonary Disease (COPD) Market was valued at USD 1.82 billion in 2021 and is expected to expand from USD 3.07 billion in 2022 to USD 29.33 billion by 2030, with a compound yearly growth rate (CAGR) of 4.50% during the forecast period (2022 - 2030).

Market Dynamics

The key factor driving the growth of the global market for chronic obstructive pulmonary disease (COPD) market size is the growing prevalence of the chronic obstructive pulmonary disease worldwide, which is expected to fuel demand for chronic obstructive pulmonary disease (COPD) drugs. For example, AS per WHO, Global Burden of Disease Study estimates a global prevalence of 251 million cases of COPD in 2016. It is estimated that COPD will become the world's third leading cause of death by 2030. Additionally, the rising geriatric population and increasing customer understanding of the new and innovative treatment options also complement market growth. Through research and development in this field to develop more innovative COPD treatment solutions may also give numerous opportunities for more market growth. However, restrictive government regulations are expected to impede business growth.

Segmentation

The global market for chronic obstructive pulmonary disease (COPD) is segmented into a type of COPD, type of treatment, end-user, and region.

The global demand for chronic obstructive pulmonary disease (COPD) was divided into emphysema and chronic bronchitis, based on type COPD.

The global market for chronic obstructive pulmonary disease (COPD) has been segmented into drugs, surgery, and oxygen therapy, by treatment. The drugs group is further segmented into the bronchodilator monotherapy and anti-inflammatory products. Bronchodilator monotherapy is further sub-segmented into short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), and anticholinergic agents. The sub-segment of anti-inflammatory drugs is further known as oral inhaled corticosteroids, and anti-leukotrienes. The surgery segment is sub-segmented into surgery for the reduction of lung volume (LVRS), lung transplantation, bullectomy, and others.

Based on end-users, the global demand for chronic obstructive pulmonary disease (COPD) has been segmented into hospitals and clinics, home care facilities, and others.

Regionally, the global chronic obstructive pulmonary disease (COPD) market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to capture a substantial share of the global market for chronic obstructive pulmonary disease (COPD) in the forecast period due to the highly advanced healthcare system and growing cases of chronic obstructive pulmonary disease (COPD) in the region. COPD, for example, is the leading cause of death in the United States, affecting 16 million Americans. Emphysema and chronic bronchitis are the two most severe forms of COPD. More than 8.9 million Americans Reliable Source were diagnosed with chronic bronchitis in 2016, and almost 75% of cases included people over the age of 45.

Europe is projected to be second-largest in the global market for chronic obstructive pulmonary disease (COPD) due to its well-developed market.

The Asia Pacific is projected to be the fastest-growing regional market due to the high number of patients suffering from COPD and the increasing prevalence of respiratory diseases.

The market for chronic obstructive pulmonary disease (COPD) in the Middle East and Africa is projected to rise gradually due to the growth of the healthcare infrastructure.

Key Players

Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players operating in the global chronic obstructive pulmonary disease (COPD) market.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com